Clinical Trial: Open-Label Extension of LOCKCYST Trial

Study Status: Completed
Recruit Status: Unknown status
Study Type: Interventional

Official Title: Open-Label Extension of the LOCKCYST Trial, LOCKCYST: Long Acting Lnareotide as as Volume Reducing Treatment of Polycystic Livers

Brief Summary:

Positive data originating from two polycystic liver patients treated with somatostatin analogues, showed a volume reduction of 38.3% and 14.9%. These two patients had complicated polycystic livers and no other therapeutic options were available.

Patients who participated in LOCKCYST trial are able to benefit from active treatment. Participants will be actively treated for 24 weeks.

Detailed Summary: van Keimpema L, de Man RA, Drenth JP. Somatostatin analogues reduce liver volume in polycystic liver disease. Gut 2008 September;57(9):1338-9.
Sponsor: Radboud University

Current Primary Outcome: Liver volume reduction [ Time Frame: 24 weeks ]

Original Primary Outcome: Same as current

Current Secondary Outcome: Kidney volume Cyst volume [ Time Frame: 24 weeks ]

Original Secondary Outcome: Same as current

Information By: Radboud University

Dates:
Date Received: October 13, 2008
Date Started: April 2008
Date Completion: August 2009
Last Updated: November 12, 2008
Last Verified: November 2008